It is well established that carriers of heterozygous pathogenic variants in MLH1, MSH2, MSH6 and PMS2 have an increased risk of colorectal and endometrial cancer and that the four MMR genes demonstrate different penetrance and expressivity [2–5]. This evidence concerns the gene MRC1 and endometrial cancer.